| 1 |
33183015 | A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report. | 2021 Jun |
1 |
| 2 |
34118789 | A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. | 2021 |
1 |
| 3 |
28538405 | Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report. | 2017 May |
1 |
| 4 |
31305693 | Erratum: Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report: Erratum. | 2017 Jul |
1 |